

1
2
3
4
5 **Quality Control by Isoleucyl-tRNA Synthetase of *Bacillus subtilis* Is Required**
6 **for Efficient Sporulation**
7
8
9
10

11
12 Elizabeth Kermgard^{1*}, Zhou Yang¹, Annika-Marisa Michel^{1,3%}, Rachel Simari^{6%}, Jacqueline
13 Wong^{1%}, Michael Ibba^{4,5,6}, and Beth A. Lazazzera^{1,2}
14

15 ¹Department of Microbiology, Immunology and Molecular Genetics and ²Molecular Biology
16 Institute, University of California, Los Angeles, California 90095, USA.

17 ³Technische Universität Braunschweig, Institut of Microbiology, Braunschweig, Germany.

18 ⁴Department of Microbiology, ⁵Center for RNA Biology, and ⁶Ohio State Biochemistry Program,
19 Ohio State University, Columbus, Ohio 43210, USA.
20
21
22

23 Corresponding Author:

24 Beth A. Lazazzera

25 Department of Microbiology, Immunology, and Molecular Genetics

26 609 Charles E. Young Dr. East

27 1602 Molecular Science Building

28 University of California, Los Angeles

29 Los Angeles, CA 90095
30

31 (310) 794-4804 (voice)

32 (310) 206-5231 (fax)

33 BethL@microbio.ucla.edu
34

35 [%]These authors contributed equally to the manuscript.

36 Current Address: * Saint Louis University School of Medicine, Saint Louis, MO 63104
37

38 Running Title: Sporulation requires quality control by IleRS

39 Keywords: Editing, quality control, IleRS, sporulation, *Bacillus subtilis*, aminoacyl-tRNA
40 synthetase

ABSTRACT

Isoleucyl-tRNA synthetase (IleRS) is an aminoacyl-tRNA synthetase whose essential function is to aminoacylate tRNA^{Ile} with isoleucine. Like some other aminoacyl-tRNA synthetases, IleRS can mischarge tRNA^{Ile} and correct this misacylation through a separate post-transfer editing function. To explore the biological significance of this editing function, we created a *ileS(T233P)* mutant of *Bacillus subtilis* that allows tRNA^{Ile} mischarging while retaining wild-type Ile-tRNA^{Ile} synthesis activity. As seen in other species defective for aminoacylation quality control, the growth rate of the *ileS(T233P)* strain was not significantly different from wild-type. When the *ileS(T233P)* strain was assessed for its ability to promote distinct phenotypes in response to starvation, the *ileS(T233P)* strain was observed to exhibit a significant defect in formation of environmentally resistant spores. The sporulation defect ranged from 3-fold to 30-fold and was due to a delay in activation of early sporulation genes. The loss of aminoacylation quality control in the *ileS(T233P)* strain resulted in the inability to compete with a wild-type strain under selective conditions that required sporulation. These data show that the quality control function of IleRS is required in *B. subtilis* for efficient sporulation and suggests that editing by aminoacyl-tRNA synthetases may be important for survival under starvation/nutrient limitation conditions.

INTRODUCTION

An essential step for the accuracy of mRNA translation is the charging of tRNAs with their cognate amino acid. Aminoacyl-tRNA synthetases (aaRS) are the enzymes that catalyze this reaction, and are a family of ancient proteins that have been conserved throughout evolution, due to their essential cellular function¹. AaRSs aminoacylate tRNAs through a two-step mechanism: 1) formation of an aminoacyl-adenylate (e.g. Ile-AMP by IleRS), and 2) aminoacylation of tRNA (e.g. Ile-tRNA^{Ile}). Due to the need for accuracy in protein synthesis, some aaRSs contain a quality control (QC) function along with their aminoacylation function². QC functions can hydrolyze either the aminoacyl-adenylate (pre-transfer editing) or the aminoacyl bond of charged tRNA (post-transfer editing). While aaRS editing functions are highly conserved in bacteria, archaea, and eukaryotes, QC is not essential for cellular growth under most laboratory conditions, and few studies have identified cellular functions that rely on aaRS editing³⁻⁷.

Isoleucine-tRNA synthetase (IleRS) possesses QC functions that discriminate between isoleucine, the non-cognate amino acid valine, and the non-proteinogenic amino acids, norvaline, a byproduct of branched-chain amino acid synthesis, and homocysteine (Hcy), a by-product from degradation of S-adenosylhomocysteine by LuxS in bacteria⁸. The aminoacylation site of IleRS is only able to discriminate Ile from Val with an accuracy of $\sim 1/200$ ⁹. IleRS improves this accuracy with two QC activities, pre- and post-transfer editing. Pre-transfer editing hydrolyzes Val-AMP in the synthetic site where aminoacylation also occurs^{10,11}, and pre-transfer editing similarly hydrolyzes Hcy-AMP¹². Post-transfer editing in contrast deacylates Val-tRNA^{Ile} in a domain, the connective peptide 1 (CP1) domain, which is distinct from the site at which

aminoacylation occurs¹³⁻¹⁶. Several studies have identified substitutions in CP1 that disrupt post-transfer editing, but retain close to wild-type levels of aminoacylation activity^{13,14,17}.

In vivo studies of IleRS mutants have begun to reveal potential cellular functions of QC by aaRSs. One primary function of quality control is to prevent misincorporation in proteins of the non-cognate and non-proteinogenic amino acids, such as valine and norvaline, respectively. Loss of IleRS QC in *E. coli* results in decreased growth when the cells are grown in high concentrations of valine or norvaline¹⁸. The *E. coli* IleRS QC mutant strain is also more sensitive to stressful conditions, including high temperatures and antibiotics, although the mechanism by which these mutant cells increase their sensitivity to stress is unknown¹⁹. Loss of quality control by IleRS may also be beneficial under certain conditions. In *E. coli* and *Acinetobacter baylyi*, loss of IleRS QC functions resulted in an improved growth rate when concentrations of isoleucine were limiting, but moderate concentrations of valine or norvaline were present^{18,20}. *Streptococcus pneumoniae* IleRS naturally lacks a post-transfer editing function, and mischarged tRNA^{Ile} serves as a substrate for peptidoglycan biosynthesis²¹. Potentially beneficial is the higher level of mutations observed in colonies of *E. coli* IleRS QC-defective cells that are allowed to age; the full mechanism by which DNA mutations arise in response to loss of quality control is also unknown²². Overall, while a number of phenotypes have been described for QC mutants, the mechanism underlying the observed changes and their broader importance remain unknown.

To address the question of what conditions require quality control for fitness, we choose to address how loss of QC by IleRS affects the function of the model Gram-positive organism, *Bacillus subtilis*. Here, we show that QC by IleRS is required for *B. subtilis*, to form environmentally-resistant endospores. These endospores are formed in response to starvation through a developmental process. This process is initiated by a master regulator, Spo0A, and

103 gene expression activated by this transcription factor is severely delayed in cells that lacking QC
104 by IleRS. Furthermore, the QC-defective IleRS strain was outcompeted by wild-type strains
105 under conditions involving periodic sporulation and outgrowth, supporting a general role for
106 quality control by aaRS under starvation or nutrient-limited conditions.

RESULTS

Cell expressing IleRS(T233P) are defective for quality control of mischarged

tRNA^{Ile}. IleRS was chosen for this study as it has a well characterized post-transfer editing activity, and substitutions that disrupt this editing without affecting aminoacylation have been made^{10,11,23}. While several studies have looked at the role of QC by IleRS in *E. coli*, relatively few studies have examined the importance of QC in other organisms. As we had previously proposed that QC maybe more critical under conditions of stress that limit cellular growth³, we chose to analyze the role of QC by IleRS in *B. subtilis*, which undergoes several distinct phenotypic or developmental shifts in response to starvation or slow growth, including the formation of environmentally-resistant endospores²⁴.

To determine the function of QC by IleRS in *B. subtilis*, a single point mutation was introduced into the *ileS* gene on the chromosome of *B. subtilis* strain JH642²⁵. The point mutation introduced causes a substitution of Thr at codon 233 to Pro. This T233P substitution was chosen because a similar substitution in IleRS of *Escherichia coli* was shown to disrupt QC by this enzyme, and while other substitutions in *E. coli* IleRS disrupt QC, the T233P substitution has virtually no effect on aminoacylation activity^{14,23}. To test whether the cells with the *ileS(T233P)* allele lacked tRNA^{Ile} QC activity, cell lysates of the wild-type *ileS* and mutant *ileS(T233P)* were tested for their ability to charge tRNA^{Ile} with either the cognate Ile or the non-cognate amino acids, Val and Leu. Lysates from the *ileS(T233P)* strain showed Ile-tRNA^{Ile} production at a similar rate as lysates from wild-type cells (Fig. 1A), indicating that the *ileS(T233P)* mutation did not affect the overall level of Ile-tRNA^{Ile} formation in cells. Similarly, the *ileS(T233P)* lysate showed only low levels of Leu-tRNA^{Ile} production, similar to that seen with lysates from wild-type cells, and consistent with the Leu not being an aminoacylation

substrate for either wild-type IleRS or IleRS(T233P) (Fig. 1C). Production of Val-tRNA^{Ile} however was significantly different between wild-type and *ileS(T233P)* cell lysates, with the *ileS(T233P)* lysate producing significantly more Val-tRNA^{Ile} than the wild-type lysate (Fig. 1B). Increased Val-tRNA^{Ile} synthesis for IleRS(T233P) may either indicate improved Val recognition and/or reduced hydrolysis of either misactivated Val-AMP or mischarged Val-tRNA^{Ile} compared with wild-type. Importantly, whatever the precise mechanism by which the T233P substitution increased Val-tRNA^{Ile} synthesis, this did not adversely affect the ability of cells to aminoacylate tRNA^{Ile} with its cognate amino acid and did disrupt QC by IleRS.

Cells expressing IleRS(T233P) are defective in sporulation. Having created a mutant strain of *B. subtilis* that expresses an QC-defective version of IleRS, we sought to determine whether *ileS(T233P)* cells had any phenotypic differences from wild-type. Any phenotypes altered in these mutant cells would suggest pathways that are sensitive to QC by IleRS. The exponential growth rate ($\Delta \ln OD_{600} / \Delta \text{time}(\text{min}) \pm \text{standard deviation}$) in rich medium, Difco Sporulation Medium (DSM), of wild-type cells and cells expressing IleRS(T233P) were not significantly different (0.020 ± 0.002 and 0.021 ± 0.002 , respectively). Similarly, in minimal medium, the exponential growth rate of these two strains was also not significantly different (0.011 ± 0.002 for wild-type cells and 0.010 ± 0.003 for the *ileS(T233P)* cells). These data are consistent with other observations of QC-defective aaRS bacterial strains are not affected for growth under standard laboratory conditions³.

As the editing function of IleRS is conserved through evolution³, and cells in natural environments are characterized by slow growth, the wild-type and *ileS(T233P)* mutant *B. subtilis* cells were assessed for their ability to form biofilms and spores, two major phenotypic states entered by this bacterium under slow-growth conditions²⁶. While wild strains of *B. subtilis* form

more robust biofilms, laboratory strain JH642 used in this study is able to form biofilms that adhere to the wells of a microtiter plate and to form flat, unstructured pellicle biofilms at air-liquid interfaces²⁷⁻³⁰. Both the *ileS(T233P)* strain and its isogenic wild-type strain formed morphologically indistinguishable pellicles that were observed as films of cells at the top of media in test tubes. In microtiter plates, there was at best a small difference in how the two strains adhered to the plates, and the $A_{570} \pm$ standard deviation was 1.4 ± 0.3 for the wild-type strain and 0.87 ± 0.02 for the *ileS(T233P)* strain. These data support a conclusion that the QC by IleRS is not essential for biofilm formation, although we cannot rule out a more prominent role for editing in wild strains of *B. subtilis*.

To assess the ability of the *ileS(T233P)* mutant cells to sporulate, these cells and the isogenic wild-type control cells were grown in DSM and incubated until sixteen hours after entry into stationary phase. At this time, the frequency of sporulation was determined as the number of heat-resistant colony-forming units (CFU)/ml relative to the total viable CFU/ml (Table 1). While the fold difference in the sporulation frequency of wild-type and the *ileS(T233P)* cells was variable, ranging from 1.5- to 15-fold, the *ileS(T233P)* cells showed a statistically significant ($p=0.015$) defect in sporulation. The variability in the sporulation phenotype is not unexpected given the stochasticity in frequency of mischarging of a tRNA.

To determine whether this sporulation defect was specific to growth in DSM, cells were grown in minimal media containing 0.1% glucose. Cells in this media exhaust glucose and transition to stationary phase at an OD_{600} of ~ 1.0 . After 16 hours in stationary phase, the frequency of sporulation was assayed (Table 1). Similar to DSM conditions, the *ileS(T233P)* mutant exhibited a statistically significant ($p>0.001$) defect in sporulation, except that the *ileS(T233P)* cells showed a larger defect in sporulation, ranging from a 4- to 30-fold defect.

The *ileS(T233P)* mutant is outcompeted by wild-type cells during cycles of sporulation. To assess the importance of the QC function of IleRS for *B. subtilis*, we asked how well the *ileS(T233P)* mutant was able to compete with the wild-type strain. We introduced into the wild-type and *ileS(T233P)* strains either a *thrC::erm* allele that encodes erythromycin resistance (Erm^R) or a *thrC::cat* allele that encodes chloramphenicol resistance (Cm^R). Cultures were inoculated with an equal mixture of both wild-type and *ileS(T233P)* cells of different antibiotic-resistance markers. In the repeats of the cultures, the antibiotic-resistance markers were swapped between the two strains to ensure that any differences observed were due to the presence of the *ileS(T233P)* mutation. The cultures were grown in DSM and passaged through a cycle of exponential growth, sporulation, and heat-kill of non-sporulated cells. A 1/10th fraction of the spores that remained after the heat-kill step were used to inoculate the next culture that was similarly passaged through a cycle of exponential growth, sporulation, and heat-kill of non-sporulated cells. This was repeated for a total of four cycles. At the end of each cycle, the percent of the spores that were from wild-type and *ileS(T233P)* cells was measured through Cm^R and Erm^R CFU/ml, as appropriate. For each independent culture started, there was a similar number of cells of each strain at the end of the first passage, consistent with no significant differences in the growth rate of these two strains. Subsequently, the number of *ileS(T233P)* cells dropped relative to the number of wild-type cells by the second or third passage, with the level of *ileS(T233P)* mutant after the fourth passage being 10⁵-fold lower than wild-type (Fig. 2). Interestingly, under these competition experiments, the *ileS(T233P)* mutant consistently showed a greater than 10-fold defect in sporulation (Fig. 2), unlike what was observed for this strain when grown individually (Table 1). These data predict that the *ileS(T233P)* mutant would go to

extinction after five cycles and strongly suggests that sporulation is one of the evolutionary pressures maintaining the QC function of IleRS in *B. subtilis*.

The QC-defective IleRS mutant is defective in expressing genes activated by the master regulator of sporulation, Spo0A. A major question from this work is why sporulation is sensitive to mistakes made by IleRS. The process of sporulation can be divided into distinct genetic and morphological stages³¹. The sporulation defect of the *ileS(T233P)* could stem from mistranslation of Ile codons, which could result in a non-functional protein that is required for sporulation. If a particular protein is negatively affected in the *ileS(T233P)* strain, we would predict the *ileS(T233P)* cells to be specifically delayed at one stage of sporulation, resulting in a strong reduction in expression of those stage-specific genes. However, mistranslation is predicted to happen randomly at Ile codons, with each cell having a different mixture of mistranslated proteins, and as a result each cell in a population could be delayed at a different stage in sporulation, and we would not observe a strong effect on any particular stage-specific gene expression at the population level.

To determine whether there is a strong decrease in stage-specific sporulation gene expression in the *ileS(T233P)* mutant, we monitored gene expression of Spo0A-controlled genes. Spo0A is the first transcription factor to become active, through phosphorylation by a phosphorelay, in the sporulation regulatory cascade³², and if Spo0A-dependent genes have strongly reduced expression, then all subsequent stage-specific sporulation genes will also have reduced expression. One of the operons activated by Spo0A is *spoIIE*, which encodes the phosphatase required for activation of the forespore specific sigma factor, Sigma-F³³. Thus, we introduced into our isogenic wild-type and *ileS(T233P)* mutant a *spoIIE-lacZ* fusion. Cells were grown in DSM, and samples were collected for β -galactosidase assay at time points just prior to

and for several hours after the entry into stationary phase. As seen in Fig. 3A, while wild-type cells induced *spoIIE* expression one hour after entry into stationary phase, *spoIIE* expression was delayed in the *ileS(T233P)* cells for five hours, after which point *spoIIE* is induced. This late induction of *spoIIE* expression in the *ileS(T233P)* mutant may explain why sporulation does occur in the mutant, albeit at a lower efficiency than wild-type cells.

Altered *spoIIE* expression in the *ileS(T233P)* mutant strain strongly suggests that Spo0A activity is reduced in this mutant strain. To confirm this, we assessed expression of a second Spo0A-activated promoter, *spoIIG*, as a *lacZ* fusion³⁴. The *spoIIG* operon encodes the mother cell-specific sigma factor, sigma-E³⁵. Similar to what was seen with *spoIIE* expression, expression of *spoIIG* was defective for several hours after entry into sporulation in the *ileS(T233P)* strain (Fig. 3B), confirming the general defect in Spo0A-controlled gene expression.

DISCUSSION

Here, we present the first strain of *B. subtilis* to lack QC for a mischarged tRNA, specifically tRNA^{Ile}. This strain has a point mutation in the endogenous copy of *ileS*, and whole cell extracts of this mutant strain mischarged tRNA^{Ile} with valine unlike the wild-type strain. While this QC-defective strain showed no defect in exponential growth, it has a significantly reduced ability to sporulate. The sporulation defect of the QC-defective IleRS strain appears to be due to weak and/or delayed activation of the first transcription factor in the sporulation cascade, Spo0A. Competition through periods of exponential growth, sporulation, and lethal challenge reveal that the *ileS(T233P)* strain was rapidly outcompeted by the wild-type strain, suggesting that starvation conditions that induce sporulation have selected for the maintenance of the IleRS QC function in *B. subtilis*.

The loss of QC by IleRS in *B. subtilis* leads to a delay in expression of sporulation genes controlled by Spo0A, the first transcription factor that is activated in the sporulation cascade. Spo0A also regulates genes involved in other processes including biofilm formation²⁶, but the *ileS(T233P)* strain exhibited a less than two-fold defect in the ability to form biofilms, much smaller than the defect observed for sporulation. Phosphorylation of Spo0A is the rate-limited step for the initiation of sporulation^{36,37}, and expression of sporulation genes requires a higher level of phosphorylated Spo0A than biofilm genes^{38,39}, suggesting that the *ileS(T233P)* strain may be defective in forming high levels of phosphorylated Spo0A. Spo0A is activated by phosphorylation through a phosphorelay⁴⁰, and there are several known negative regulators of this phosphorelay. Future research will address what step along this Spo0A activation pathway is affected in the *ileS(T233P)* mutant or whether there is a Spo0A-independent mechanism that is affecting the expression of these *spoII* genes. Understanding how *B. subtilis* controls sporulation has allowed researchers to identify how cells sense cell cycle problems, which are amplified by

257 checkpoints that delay sporulation, including DNA replication, chromosome partitioning, and
258 tricarboxylic cycle metabolism^{41,42}, and research into how loss of QC by IleRS affects
259 sporulation could reveal a novel checkpoint. It is not known at this time if the requirement of QC
260 for sporulation is specific to IleRS or whether loss of QC by other aaRSs will similarly disrupt
261 sporulation in *B. subtilis*. Intriguingly, the *ileS* gene of *B. subtilis* and other endospore-forming
262 species is adjacent to a gene, *glyA*, required for spore germination⁴³.

263 What causes sporulation to be so sensitive to the loss of QC by IleRS? IleRS could
264 encounter conditions that promote a higher rate of mischarging of tRNA^{Ile} in stationary phase,
265 through a higher ratio of non-cognate Val to cognate Ile. Alternatively, the rate of mischarging,
266 and subsequent mistranslation, may be identical between exponential growth and stationary
267 phase, and a protein(s) involved in sporulation may be particularly sensitive to mistranslation. A
268 further possibility is that there is a higher ratio of charged to uncharged tRNA^{Ile} as a result of loss
269 of QC by IleRS, and this altered ratio may delay activation of the sporulation pathway. *E. coli*
270 cells expressing an editing-defective form of the phenylalanine tRNA synthetase (PheRS), have a
271 higher ratio of charged to uncharged tRNA^{Phe} under amino acid starvation and are unable to
272 mount a stringent response⁴⁴. In *B. subtilis*, the stringent response is induced by uncharged
273 tRNAs and has been shown to activate sporulation⁴⁵. The higher ratio of charged to uncharged
274 tRNA^{Ile} in *B. subtilis* may also affect the putative ILE-T-Box (i.e. riboswitch) of *ileS*, which
275 could alter the levels of IleRS and possibly exacerbate the problems caused by loss of QC^{46,47}.
276 Biosynthesis of Ile and other branched-chain amino acids (BCAA) is not predicted to be directly
277 affected in the IleRS QC-defective mutant, as aaRS are highly specific for their cognate tRNA
278 and the BCAA biosynthesis operon *ilvBHC-leuABCD* is controlled by tRNA^{Leu} and a LEU-T-
279 Box⁴⁸. Future experiments to address the potential models outlined here for why quality control

by IleRS is critical for sporulation, but not exponential growth, will require measuring cellular amino acid pools, the level of the stringent response alarmone, ppGpp, mistranslation, and charged tRNA^{Ile} in actively growing and sporulating cells.

Sporulation by *B. subtilis* is a developmental process induced by starvation, specifically limitation for carbon, nitrogen, or phosphorous⁴⁹⁻⁵¹, and it is the major state in which *B. subtilis* is isolated from the environment⁵². Cells lacking QC by IleRS are rapidly outcompeted by wild-type cells under conditions requiring sporulation, which strongly argues that sporulation is the physiological condition that selects for the maintenance of QC by IleRS in *B. subtilis*. These data further suggest that the primary role of QC by IleRS in other species, and possibly QC by other aaRSs, may be in allowing survival of cells that have a severely reduced growth rate. Consistent with this, QC by alanine tRNA synthetase (AlaRS) was shown to be required in terminally differentiated mouse neuronal cells and cardiomyocytes, non-growing or slowly-growing cell populations^{5,53}. Intriguingly, QC by some aaRSs has been lost from mitochondria and *Mycoplasma* species, many of which are intracellular parasites⁵⁴⁻⁵⁷. This latter finding suggests that, in the absence of changing environmental conditions, QC by aaRSs may not be required and is consistent with the suggestion of the work presented here that QC is required by cells that must transition from rapid growth to slow-growth/stationary phase induced by nutrient limitation.

In summary, we have shown for the first time that the quality control function of a tRNA synthetase is critical for sporulation in *B. subtilis*. The IleRS QC was required for activating the genes controlled by the master transcription factor, Spo0A, and cells lacking IleRS QC were rapidly lost from a mixed population when a selection for sporulation was applied. These data suggest that the QC function of tRNA synthetases may be conserved to deal with particular stress

303 conditions that are encountered by cells as their growth slows or they enter stationary phase in
304 response to nutrient limitation.

EXPERIMENTAL PROCEDURES

tRNA Preparation. *Bacillus subtilis* tRNA^{Ile} was transcribed *in vitro* as previously described⁵⁸.

Cell Free Extract Preparation. *B. subtilis* tRNA-free cell free extracts were prepared as described⁵⁹, using strains containing either a wild-type *ileS* gene or an editing deficient allele of *ileS* (*ileS*(T233P)), except EDTA-free protease inhibitor (Roche) was used during lysis to replace PMSF. Briefly, the supernatant following ultracentrifugation was loaded onto DEAE Sephacel (GE) resin. Cell free extracts were quantified using a BCA Protein Assay kit (Thermo Scientific Pierce).

Aminoacylation Assays. Aminoacylation assays using cell free extracts of wild-type *ileS* and *ileS*(T233P) strains were performed as previously described²¹. Each reaction contained 450 µg extract protein, 1070 ng/µL of *B. subtilis* tRNA^{Ile}, 0.1 mM cognate [¹⁴C]Ile at 200 cpm/pmol (Moravek Biochemicals), 0.15 mM non-cognate [¹⁴C]Val at 120 cpm/pmol (PerkinElmer), and 0.3 mM non-cognate [¹⁴C]Leu at 120 cpm/pmol (Moravek Biochemicals).

Growth conditions. *E. coli* and *B. subtilis* strains were routinely grown in Luria-Bertani (LB) medium. For sporulation assays, *B. subtilis* strains were grown in either Difco sporulation medium (DSM)⁶⁰ or S7₅₀ minimal medium with 0.1% glucose⁶¹. Both *E. coli* and *B. subtilis* strains were grown at 37°C. Antibiotics were used as required at the following concentrations: ampicillin 100 µg/ml, chloramphenicol 5 µg/ml, erythromycin 0.5 µg/ml, and tetracycline 12.5 µg/ml. The growth rate was measured as the slope of the line from the natural log of the OD₆₀₀ readings versus the time of incubation in minutes. Only points in exponential growth were used for a line fit, and only line fits that gave an R-value greater than 0.99 were considered valid.

Strain construction. *E. coli* strain Top10 (Invitrogen) was used for the routine

construction and maintenance of plasmids. The *B. subtilis* strains used in this study are all derivatives of the JH642 strain, which contains the *trpC2* and *pheA1* mutations²⁵ and were constructed by transformation of genetically competent cells with chromosomal DNA or plasmids using standard protocols⁶⁰. Gene replacement was verified using PCR.

The *B. subtilis ileS(T233P)* strain was constructed by transformation with a plasmid, pBL4566, containing the *ileS(T233P)* gene. The pBL4566 plasmid is a derivative of pJet1.2 (Thermo Fisher) that contains a restriction site for the I-SceI meganuclease⁶² and the *cat* gene for chloramphenicol resistance. The *ileS* gene was PCR amplified with primers ileS-F (5'-GCATGGATCCAAGGAATAAATTCTCTGATTA) and ileS-R (5'-GCATAGATCTGCATATCGGTCAACTGAACGC) and ligated to pJet1.2 according to the instructions of the CloneJET PCR Cloning Kit (ThermoFisher Scientific). An I-SceI-*cat* cassette was constructed by PCR amplification with pJH101⁶³ as a template and primers I-SceI-*cat*-A (5'-

ATGCCTGCAGTAGGGATAACAGGGTAATTATTGGGCGCTCTTCCGCTAAGCATGCGT
TACCCTTATTATCAAGA) and I-SceI-*cat*-B (5' –

ATGCCTGCAGGCGAGTCAGTGAGCGAGGAAGCAAGCATGCGGAGCTGTAATATAAAA
AC), in which the underlined sequence corresponds to the *cat* gene, the I-SceI site is bold, and

PstI restriction sites are italicized. Both the I-SceI-*cat* PCR and the pJet1.2-*ileS* plasmid were digested with PstI and ligated, to yield a pJet-*ileS*-I-SceI-*cat* plasmid. This plasmid was subjected to site-directed mutagenesis using primers T233P-F (5'-

GCATCATCATTTGGACACCAACGCCGTGGACAATT) and its reverse complement (the bold, underlined nucleotide is the introduced mutation), according to directions of Quikchange

351 Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). The presence of the mutation
 352 was confirmed by DNA sequencing, and the resulting plasmid was named pBL4566.

353 To transfer the *ileS(T233P)* allele on pBL4566 to the chromosome of *B. subtilis*, a wild-
 354 type strain of *B. subtilis*, JH642²⁵, was transformed with pBL4566, and transformants were
 355 selected on plates containing chloramphenicol. The resulting strain, BL4568, which has
 356 pBL4566 integrated into its chromosome at the *ileS* locus, has two alleles of *ileS*, one wild-type
 357 and one *ileS(T233P)*, flanking the pJet1.2 plasmid backbone and the I-SceI-*cat* cassette. To
 358 return the chromosome to just one copy of *ileS* and remove the pBL4566 plasmid, the pBKJ223
 359 plasmid that expresses the I-SceI meganuclease⁶⁴ was transformed into BAL4568, and
 360 transformations were selected on plates containing tetracycline. I-SceI cleaves the chromosome
 361 at the I-SceI restriction site on the pBL4566 plasmid, and repair of this DNA break by
 362 homologous recombination results in a strain that has removed the plasmid sequences and
 363 restored the native *ileS* chromosomal structure, with the *ileS* allele present being either wild-type
 364 or *ileS(T233P)*. To screen for cells that have lost the plasmid sequence, transformants were
 365 screened for chloramphenicol sensitivity. The *ileS* allele present in the chloramphenicol-sensitive
 366 clones were screened by PCR amplification and DNA sequencing, including the genes to either
 367 side of *ileS*, *ylmA* and *divIVA*. One strain with the *ileS(T233P)* allele and one with the wild-type
 368 *ileS* allele were selected. To remove pBKJ223 from the desired clones, cells were grown in LB
 369 liquid cultures lacking antibiotic selection. Colonies from these cultures were streak-purified on
 370 LB agar plates and then screened for tetracycline sensitivity. Two tetracycline-sensitive clones,
 371 one wild-type *ileS* and one *ileS(T233P)*, were named BAL4574 and BAL4571, respectively. To
 372 assay expression of sporulation genes, *thrC::(spoIIE-lacZ, erm)*^{65,66} and *Spβ::(spoIIG-lacZ, cat)*
 373⁶⁷ were introduced into BAL4574 (wild-type) and BAL4571 (*ileS(T233P)*).

Sporulation Assays. To assess the *ileS(T233P)* mutant for sporulation, strains were assessed for the presence of heat-resistant spores, as previously described⁶⁰. Briefly, cells were grown in liquid Difco Sporulation Medium (DSM) until 16 hours after the onset of stationary phase. At this time, the total viable CFU/ml was measured and then the cultures were heated at 80 °C for 20 minutes, and the heat-resistant CFU/ml was measured as the number of spores present.

β-Galactosidase Assays. Cells were grown as described above for sporulation assays, except that samples were harvested throughout the exponential growth phase and several hours past the entry of the cultures into stationary phase. The cells were then harvested by centrifugation, and resuspended in Z-Buffer, and β-galactosidase activity was measured as previously described⁶⁸. β-galactosidase-specific activity is presented as (ΔA_{420} per minute per ml of culture per $OD_{600}) \times 1000$).

Biofilm formation Assays. Cells were grown for 24 hours in polyvinyl chloride microtiter plates in Biofilm Growth Medium, a modified LB based medium supplemented with 124 mM potassium phosphate pH 7.0, 15 mM ammonium sulphate, 3.4 mM sodium citrate, 0.01 mM $MgSO_4$, and 0.1% glucose as previously described²⁸⁻³⁰. After incubation, the wells were washed twice and subsequently stained with crystal violet. The wells were rinsed to remove any non-adherent crystal violet and treated with a solubilizing solution of 80% ethanol, 20% acetic acid; the A_{570} of the solution was then measured. The A_{570} of 16-24 wells were averaged. When the SEM (standard error of the mean) of the A_{570} measurements obtained for the 16-24 wells was <10% of the mean, the assay was considered valid. Each assay was repeated on at least three independent occasions, and the averages from all valid assays were averaged to determine the level of biofilm formation for a strain.

397 **Growth of pellicle biofilms.** Bacterial cells were inoculated at OD₆₀₀ 0.025 into Biofilm
398 Growth Medium and grown with shaking until OD₆₀₀ ~1.0. The cells were diluted into fresh
399 Biofilm Growth Medium to an OD₆₀₀ of 0.01 and 5 ml were added to culture test tubes. The
400 tubes were incubated at 37°C for 48 hours with no shaking, at which times the pellicles were
401 imaged.
402

ACKNOWLEDGEMENTS

We thank members of the Lazazzera and Ibba labs for comments on the manuscript. We particularly thank Sharon Hoover, Ph.D. for her suggestions for and assistance with experiments. Plasmid pBKJ223 was a kind gift from Scott Stibitz, Ph.D. (NIH). This research was supported by National Science Foundation (MCB 1412773 to B.L.; MCB 1412611 to M.I.). J.W. was supported through a Biomedical Research Summer Scholarship from UCLA.

AUTHOR CONTRIBUTIONS

EK, MI, and BAL contributed to the conception or design of the study, EK, ZY, A-MM, RS, and JW contributed to the acquisition, analysis, and interpretation of the data, and EK and BAL were involved in writing of the manuscript.

ADDITIONAL INFORMATION

Competing financial interests: The authors declare no competing financial interests.

REFERENCES

- 1 Perona, J. J. & Gruic-Sovulj, I. Synthetic and editing mechanisms of aminoacyl-tRNA synthetases. *Top Curr Chem* **344**, 1-41, doi:10.1007/128_2013_456 (2014).
- 2 Yadavalli, S. S. & Ibba, M. Quality control in aminoacyl-tRNA synthesis its role in translational fidelity. *Adv Protein Chem Struct Biol* **86**, 1-43, doi:10.1016/B978-0-12-386497-0.00001-3 (2012).
- 3 Reynolds, N. M., Lazazzera, B. A. & Ibba, M. Cellular mechanisms that control mistranslation. *Nat Rev Microbiol* **8**, 849-856, doi:10.1038/nrmicro2472 (2010).
- 4 Schimmel, P. Development of tRNA synthetases and connection to genetic code and disease. *Protein Sci* **17**, 1643-1652, doi:10.1110/ps.037242.108 (2008).
- 5 Liu, Y. *et al.* Deficiencies in tRNA synthetase editing activity cause cardioproteinopathy. *Proc Natl Acad Sci U S A* **111**, 17570-17575, doi:10.1073/pnas.1420196111 (2014).
- 6 Cvetic, N., Palencia, A., Halasz, I., Cusack, S. & Gruic-Sovulj, I. The physiological target for LeuRS translational quality control is norvaline. *EMBO J* **33**, 1639-1653, doi:10.15252/embj.201488199 (2014).
- 7 Bullwinkle, T. J. *et al.* Oxidation of cellular amino acid pools leads to cytotoxic mistranslation of the genetic code. *Elife* **3**, doi:10.7554/eLife.02501 (2014).
- 8 Pei, D. & Zhu, J. Mechanism of action of S-ribosylhomocysteinase (LuxS). *Curr Opin Chem Biol* **8**, 492-497, doi:10.1016/j.cbpa.2004.08.003 (2004).
- 9 Schmidt, E. & Schimmel, P. Mutational isolation of a sieve for editing in a transfer RNA synthetase. *Science* **264**, 265-267 (1994).
- 10 Dulic, M., Perona, J. J. & Gruic-Sovulj, I. Determinants for tRNA-dependent pretransfer editing in the synthetic site of isoleucyl-tRNA synthetase. *Biochemistry* **53**, 6189-6198, doi:10.1021/bi5007699 (2014).
- 11 Dulic, M., Cvetic, N., Perona, J. J. & Gruic-Sovulj, I. Partitioning of tRNA-dependent editing between pre- and post-transfer pathways in class I aminoacyl-tRNA synthetases. *J Biol Chem* **285**, 23799-23809, doi:10.1074/jbc.M110.133553 (2010).
- 12 Sikora, M. & Jakubowski, H. Homocysteine editing and growth inhibition in Escherichia coli. *Microbiology* **155**, 1858-1865, doi:10.1099/mic.0.026609-0 (2009).
- 13 Hendrickson, T. L. *et al.* Mutational separation of two pathways for editing by a class I tRNA synthetase. *Mol Cell* **9**, 353-362 (2002).
- 14 Hendrickson, T. L., Nomanbhoy, T. K. & Schimmel, P. Errors from selective disruption of the editing center in a tRNA synthetase. *Biochemistry* **39**, 8180-8186 (2000).
- 15 Bishop, A. C., Beebe, K. & Schimmel, P. R. Interstice mutations that block site-to-site translocation of a misactivated amino acid bound to a class I tRNA synthetase. *Proc Natl Acad Sci U S A* **100**, 490-494, doi:10.1073/pnas.0237335100 (2003).
- 16 Cvetic, N. *et al.* Naturally Occurring Isoleucyl-tRNA Synthetase without tRNA-dependent Pre-transfer Editing. *J Biol Chem* **291**, 8618-8631, doi:10.1074/jbc.M115.698225 (2016).
- 17 Bishop, A. C., Nomanbhoy, T. K. & Schimmel, P. Blocking site-to-site translocation of a misactivated amino acid by mutation of a class I tRNA synthetase. *Proc Natl Acad Sci U S A* **99**, 585-590, doi:10.1073/pnas.012611299 (2002).
- 18 Pezo, V. *et al.* Artificially ambiguous genetic code confers growth yield advantage. *Proc Natl Acad Sci U S A* **101**, 8593-8597, doi:10.1073/pnas.0402893101 (2004).
- 19 Bacher, J. M., de Crecy-Lagard, V. & Schimmel, P. R. Inhibited cell growth and protein functional changes from an editing-defective tRNA synthetase. *Proc Natl Acad Sci U S A* **102**, 1697-1701, doi:10.1073/pnas.0409064102 (2005).

465 20 Bacher, J. M., Waas, W. F., Metzgar, D., de Crecy-Lagard, V. & Schimmel, P. Genetic code
466 ambiguity confers a selective advantage on *Acinetobacter baylyi*. *Journal of bacteriology* **189**,
467 6494-6496, doi:10.1128/JB.00622-07 (2007).

468 21 Shepherd, J. & Ibba, M. Relaxed substrate specificity leads to extensive tRNA mischarging by
469 *Streptococcus pneumoniae* class I and class II aminoacyl-tRNA synthetases. *MBio* **5**, e01656-
470 01614, doi:10.1128/mBio.01656-14 (2014).

471 22 Bacher, J. M. & Schimmel, P. An editing-defective aminoacyl-tRNA synthetase is mutagenic in
472 aging bacteria via the SOS response. *Proc Natl Acad Sci U S A* **104**, 1907-1912,
473 doi:10.1073/pnas.0610835104 (2007).

474 23 Fukunaga, R., Fukai, S., Ishitani, R., Nureki, O. & Yokoyama, S. Crystal structures of the CP1
475 domain from *Thermus thermophilus* isoleucyl-tRNA synthetase and its complex with L-valine. *J*
476 *Biol Chem* **279**, 8396-8402, doi:10.1074/jbc.M312830200 (2004).

477 24 Higgins, D. & Dworkin, J. Recent progress in *Bacillus subtilis* sporulation. *FEMS Microbiol Rev* **36**,
478 131-148, doi:10.1111/j.1574-6976.2011.00310.x (2012).

479 25 Perego, M., Spiegelman, G. B. & Hoch, J. A. Structure of the gene for the transition state
480 regulator, *abrB*: regulator synthesis is controlled by the *spo0A* sporulation gene in *Bacillus*
481 *subtilis*. *Molecular microbiology* **2**, 689-699 (1988).

482 26 Lopez, D., Vlamakis, H. & Kolter, R. Generation of multiple cell types in *Bacillus subtilis*. *FEMS*
483 *Microbiology Reviews* **33**, 152-163, doi:10.1111/j.1574-6976.2008.00148.x (2009).

484 27 Hamon, M. A. & Lazazzera, B. A. The sporulation transcription factor *Spo0A* is required for
485 biofilm development in *Bacillus subtilis*. *Molecular microbiology* **42**, 1199-1209 (2001).

486 28 Hamon, M. A., Stanley, N. R., Britton, R. A., Grossman, A. D. & Lazazzera, B. A. Identification of
487 *AbrB*-regulated genes involved in biofilm formation by *Bacillus subtilis*. *Molecular microbiology*
488 **52**, 847-860, doi:10.1111/j.1365-2958.2004.04023.x (2004).

489 29 Stanley, N. R. & Lazazzera, B. A. Defining the genetic differences between wild and domestic
490 strains of *Bacillus subtilis* that affect poly-gamma-dl-glutamic acid production and biofilm
491 formation. *Molecular microbiology* **57**, 1143-1158, doi:10.1111/j.1365-2958.2005.04746.x
492 (2005).

493 30 Terra, R., Stanley-Wall, N. R., Cao, G. & Lazazzera, B. A. Identification of *Bacillus subtilis* *SipW* as
494 a bifunctional signal peptidase that controls surface-adhered biofilm formation. *Journal of*
495 *bacteriology* **194**, 2781-2790, doi:10.1128/jb.06780-11 (2012).

496 31 Stragier, P. & Losick, R. Molecular genetics of sporulation in *Bacillus subtilis*. *Annu Rev Genet* **30**,
497 297-241, doi:10.1146/annurev.genet.30.1.297 (1996).

498 32 Stephenson, K. & Lewis, R. J. Molecular insights into the initiation of sporulation in Gram-
499 positive bacteria: new technologies for an old phenomenon. *FEMS Microbiology Reviews* **29**,
500 281-301, doi:10.1016/j.fmrre.2004.10.003 (2005).

501 33 Yudkin, M. D. & Clarkson, J. Differential gene expression in genetically identical sister cells: the
502 initiation of sporulation in *Bacillus subtilis*†. *Molecular microbiology* **56**, 578-589,
503 doi:10.1111/j.1365-2958.2005.04594.x (2005).

504 34 Satola, S., Kirchman, P. A. & Moran, C. P., Jr. *Spo0A* binds to a promoter used by sigma A RNA
505 polymerase during sporulation in *Bacillus subtilis*. *Proc Natl Acad Sci U S A* **88**, 4533-4537 (1991).

506 35 Kenney, T. J. & Moran, C. P., Jr. Organization and regulation of an operon that encodes a
507 sporulation-essential sigma factor in *Bacillus subtilis*. *Journal of bacteriology* **169**, 3329-3339
508 (1987).

509 36 Chastanet, A. *et al.* Broadly heterogeneous activation of the master regulator for sporulation in
510 *Bacillus subtilis*. *Proc Natl Acad Sci U S A* **107**, 8486-8491, doi:10.1073/pnas.1002499107 (2010).

511 37 Eswaramoorthy, P. *et al.* The threshold level of the sensor histidine kinase KinA governs entry
512 into sporulation in *Bacillus subtilis*. *Journal of bacteriology* **192**, 3870-3882,
513 doi:10.1128/JB.00466-10 (2010).

514 38 Fujita, M. & Losick, R. Evidence that entry into sporulation in *Bacillus subtilis* is governed by a
515 gradual increase in the level and activity of the master regulator Spo0A. *Genes Dev* **19**, 2236-
516 2244, doi:10.1101/gad.1335705 (2005).

517 39 Fujita, M., Gonzalez-Pastor, J. E. & Losick, R. High- and low-threshold genes in the Spo0A regulon
518 of *Bacillus subtilis*. *Journal of bacteriology* **187**, 1357-1368, doi:10.1128/jb.187.4.1357-
519 1368.2005 (2005).

520 40 Piggot, P. J. & Hilbert, D. W. Sporulation of *Bacillus subtilis*. *Current opinion in microbiology* **7**,
521 579-586, doi:10.1016/j.mib.2004.10.001 (2004).

522 41 Grossman, A. D. Genetic networks controlling the initiation of sporulation and the development
523 of genetic competence in *Bacillus subtilis*. *Annu Rev Genet* **29**, 477-508,
524 doi:10.1146/annurev.ge.29.120195.002401 (1995).

525 42 Errington, J. Regulation of endospore formation in *Bacillus subtilis*. *Nat Rev Microbiol* **1**, 117-126,
526 doi:10.1038/nrmicro750 (2003).

527 43 Traag, B. A., Pugliese, A., Eisen, J. A. & Losick, R. Gene conservation among endospore-forming
528 bacteria reveals additional sporulation genes in *Bacillus subtilis*. *Journal of bacteriology* **195**,
529 253-260, doi:10.1128/JB.01778-12 (2013).

530 44 Bullwinkle, T. J. & Ibba, M. Translation quality control is critical for bacterial responses to amino
531 acid stress. *Proc Natl Acad Sci U S A* **113**, 2252-2257, doi:10.1073/pnas.1525206113 (2016).

532 45 Tojo, S., Hirooka, K. & Fujita, Y. Expression of kinA and kinB of *Bacillus subtilis*, necessary for
533 sporulation initiation, is under positive stringent transcription control. *Journal of bacteriology*
534 **195**, 1656-1665, doi:10.1128/jb.02131-12 (2013).

535 46 Grundy, F. J. *et al.* The *Staphylococcus aureus* ileS gene, encoding isoleucyl-tRNA synthetase, is a
536 member of the T-box family. *Journal of bacteriology* **179**, 3767-3772 (1997).

537 47 Sherwood, A. V., Grundy, F. J. & Henkin, T. M. T box riboswitches in Actinobacteria: translational
538 regulation via novel tRNA interactions. *Proc Natl Acad Sci U S A* **112**, 1113-1118,
539 doi:10.1073/pnas.1424175112 (2015).

540 48 Grandoni, J. A., Fulmer, S. B., Brizzio, V., Zahler, S. A. & Calvo, J. M. Regions of the *Bacillus*
541 *subtilis* *ilv-leu* operon involved in regulation by leucine. *Journal of bacteriology* **175**, 7581-7593
542 (1993).

543 49 Freese, E. in *Sporulation & Germination - Proceedings of the VIII International Spores Conference*
544 (eds H. S. Levinson, A. L. Sonenshein, & D. J. Tipper) 1-12 (American Society for Microbiology,
545 1981).

546 50 Losick, R. & Youngman, P. in *Microbial Development* (eds R. Losick & L. Shapiro) 63-68 (Cold
547 Spring Harbor Laboratory Press, 1984).

548 51 Sonenshein, A. L. in *Molecular biology of microbial differentiation* (eds J. A. Hoch & P. Setlow)
549 185-193 (American Society of Microbiology, 1985).

550 52 Nicholson, W. L. Roles of *Bacillus* endospores in the environment. *Cellular and molecular life*
551 *sciences : CMLS* **59**, 410-416 (2002).

552 53 Lee, J. W. *et al.* Editing-defective tRNA synthetase causes protein misfolding and
553 neurodegeneration. *Nature* **443**, 50-55, doi:10.1038/nature05096 (2006).

554 54 Ye, Q. *et al.* Degenerate CP1 Domain from Human Mitochondrial Leucyl-tRNA Synthetase.
555 *Journal of Biological Chemistry*, doi:10.1074/jbc.M115.672824 (2015).

556 55 Roy, H., Ling, J., Alfonzo, J. & Ibba, M. Loss of editing activity during the evolution of
557 mitochondrial phenylalanyl-tRNA synthetase. *J Biol Chem* **280**, 38186-38192,
558 doi:10.1074/jbc.M508281200 (2005).

- 56 Li, L. *et al.* Naturally occurring aminoacyl-tRNA synthetases editing-domain mutations that cause mistranslation in Mycoplasma parasites. *Proc Natl Acad Sci U S A* **108**, 9378-9383, doi:10.1073/pnas.1016460108 (2011).
- 57 Yadavalli, S. S. & Ibba, M. Selection of tRNA charging quality control mechanisms that increase mistranslation of the genetic code. *Nucleic Acids Res* **41**, 1104-1112, doi:10.1093/nar/gks1240 (2013).
- 58 Roy, H., Ling, J., Irnov, M. & Ibba, M. Post-transfer editing in vitro and in vivo by the beta subunit of phenylalanyl-tRNA synthetase. *EMBO J* **23**, 4639-4648, doi:10.1038/sj.emboj.7600474 (2004).
- 59 Curnow, A. W., Tumbula, D. L., Pelaschier, J. T., Min, B. & Soll, D. Glutamyl-tRNA(Gln) amidotransferase in Deinococcus radiodurans may be confined to asparagine biosynthesis. *Proc Natl Acad Sci U S A* **95**, 12838-12843 (1998).
- 60 Harwood, C. R. & Cutting, S. M. *Molecular biological methods for Bacillus*. (Wiley, 1990).
- 61 Solomon, J. M., Lazazzera, B. A. & Grossman, A. D. Purification and characterization of an extracellular peptide factor that affects two different developmental pathways in Bacillus subtilis. *Genes Dev* **10**, 2014-2024 (1996).
- 62 Viret, J. F. Meganuclease I-SceI as a Tool for the Easy Subcloning of Large DNA Fragments Devoid of Selection Marker. *Biotechniques* **14**, 325-326 (1993).
- 63 Ferrari, F. A., Nguyen, A., Lang, D. & Hoch, J. A. Construction and properties of an integrable plasmid for Bacillus subtilis. *Journal of bacteriology* **154**, 1513-1515 (1983).
- 64 Janes, B. K. & Stibitz, S. Routine markerless gene replacement in Bacillus anthracis. *Infect Immun* **74**, 1949-1953, doi:10.1128/iai.74.3.1949-1953.2006 (2006).
- 65 Arigoni, F., Guerout-Fleury, A. M., Barak, I. & Stragier, P. The SpoII_E phosphatase, the sporulation septum and the establishment of forespore-specific transcription in Bacillus subtilis: a reassessment. *Molecular microbiology* **31**, 1407-1415 (1999).
- 66 Prepiak, P. *et al.* MecA dampens transitions to spore, biofilm exopolysaccharide and competence expression by two different mechanisms. *Molecular microbiology* **80**, 1014-1030, doi:10.1111/j.1365-2958.2011.07627.x (2011).
- 67 Kenney, T. J., York, K., Youngman, P. & Moran, C. P., Jr. Genetic evidence that RNA polymerase associated with sigma A factor uses a sporulation-specific promoter in Bacillus subtilis. *Proc Natl Acad Sci U S A* **86**, 9109-9113 (1989).
- 68 Miller, J. H. *Experiments in molecular genetics*. (Cold Spring Harbor Laboratory, 1972).

592 **Table 1:** Sporulation Frequency of Wild-Type and IleRS(T233P) Cells

Trial	Wild-Type			IleRS(T233P)		
	Viable ^a	Spores ^b	Frequency ^c	Viable ^a	Spores ^b	Frequency ^c
Difco Sporulation Media						
1	5.9 x 10 ⁸	3.5 x 10 ⁸	60 %	3.6 x 10 ⁸	1.3 x 10 ⁸	35 %
2	6.8 x 10 ⁸	3.8 x 10 ⁸	56%	3.5 x 10 ⁸	1.2 x 10 ⁸	34 %
3	4.9 x 10 ⁸	3.8 x 10 ⁸	78 %	3.2 x 10 ⁸	1.6 x 10 ⁷	5 %
4	4.6 x 10 ⁸	3.6 x 10 ⁸	77 %	6.0 x 10 ⁸	7.1 x 10 ⁷	12 %
5	3.4 x 10 ⁸	3.5 x 10 ⁸	100 %	3.5 x 10 ⁸	2.5 x 10 ⁷	71 %
Glucose Minimal Media						
1	2.7 x 10 ⁸	1.8 x 10 ⁸	67%	1.6 x 10 ⁸	3.4 x 10 ⁶	2.1%
2	2.7 x 10 ⁸	2.3 x 10 ⁸	85%	1.8 x 10 ⁸	1.3 x 10 ⁷	7.2%
3	9.1 x 10 ⁷	9.2 x 10 ⁷	100%	1.1 x 10 ⁸	3.1 x 10 ⁷	27%

593 ^a Reported are the CFU/ml of the cultures after 16 hours of incubation in stationary phase.

594 ^b After testing for viable cells, the cultures were heat treated at 80°C for 20 minutes and then
595 plated for CFU/ml counts.

596 ^c The frequency of sporulation was calculated as [(spores CFU/ml)/(viable CFU/ml)*100].

597
598




Figure 1. The *ileS(T233P)* strain mischarges tRNA^{Ile} with valine. Cell extracts of BAL4574 (WT; filled squares) and BAL4571(*ileS(T233P)*; open circles) were assayed for their ability to aminoacylate tRNA^{Ile} with ¹⁴C versions of isoleucine (A.), valine (B.), or leucine (C.). Plotted is the average pmoles of the radiolabeled tRNA from three reactions versus the time after the addition of tRNA^{Ile} and the radiolabeled amino acid. Error bars are standard error of the mean. Lines are best fits of the data to a Michaelis-Menton equation, with the exception of WT in panels B and C, as the basal level of aminoacylation observed could not be fit.




Figure 2. The *ileS*(T233P) strain is outcompeted by wild-type cells. Derivatives of BAL4574 (WT; circles) and BAL4571 (*ileS*(T233P); squares), which carried either erythromycin-resistant or chloramphenicol-resistant genes, were mixed in equal numbers in DSM and incubated until 16 hours post the onset of stationary phase. At that time, the total CFU/ml (open symbols) was assessed for both cell types. The cultures were then heated to kill vegetative cells, and the CFU/ml of spores (filled symbols) was assessed for both cell types. A 1/10th volume of the spores was then transferred to a new DSM culture, and the process was repeated for four days. Plotted is the average CFU/ml of four separate cultures versus the day of the competition. Error bars are standard error of the mean.




Figure 3. Expression of a Spo0A-activated gene is delayed in the *ileS(T233P)* mutant. Strains carrying a *spoIIE-lacZ* (A.) or *spoIIG-lacZ* (B.) fusion were grown in DSM. Samples were removed periodically, and the β -galactosidase specific activity ($(\Delta A_{420}$ per minute per ml of culture per $OD_{600}) \times 1000$) was measured and plotted versus the time the sample was harvested relative to the time at which stationary phase for the culture commenced. The strains grown in panel A were BAL4575 (WT; closed squares) and BAL4576 (*ileS(T233P)*; open circles), and strains grown in panel B were BAL4418 (WT; closed squares) and BAL4419 (*ileS(T233P)*; open circles). The data shown are representative of at least three independent experiments.